Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOC1021 and pIFN in Refractory Melanoma
NCT07288112Phase 2Recruiting
- Sponsor
- Diakonos Oncology
- Start
- Apr 2026
- Primary completion
- Jan 2031
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dubodencel in melanoma, sponsored by Diakonos Oncology. Primary endpoints: Dose Limiting Toxicities at 6 weeks and Objective Response Rate at 5 years. Started Apr 2026; status: recruiting.
02
Drugs
dubodencel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07288112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288112.